Search Results

You are looking at 41 - 50 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Brooke E. Wilson, Sallie-Anne Pearson, Michael B. Barton, and Eitan Amir

ability to test treatments across different populations with unique attributes, genetics, and ethnicity. When pooling outcomes across regions and countries, studies assume that treatment effects are similar. However, even among high-income countries with

Full access

Ryan D. Nipp, Brandon Temel, Charn-Xin Fuh, Paul Kay, Sophia Landay, Daniel Lage, Esteban Franco-Garcia, Erin Scott, Erin Stevens, Terrence O’Malley, Supriya Mohile, William Dale, Lara Traeger, Ardeshir Z. Hashmi, Vicki Jackson, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

population accounts for nearly three-fourths of cancer deaths. 1 Older adults diagnosed with cancer also experience worse survival outcomes than their younger counterparts, which may result from differential treatment of the geriatric cancer population. 2

Full access

Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou

the role of PORT in survival outcome, which would help surgeons and radiologists provide individualized recommendations regarding PORT to patients with ACC. Patients and Methods Patient Characteristics From January 2000 through December 2017, 480

Full access

Daniel Boakye, Viola Walter, Lina Jansen, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

recurrence-related outcomes is limited. It is also unclear whether the impact of comorbidities varies by tumor stage or site. In some previous studies, the effect of comorbidity on overall survival (OS) appeared to be more pronounced in patients with early

Full access

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

currently accepted framework for quality measurement in oncology, in part based on the structure, process, and outcome model for assessment of healthcare quality defined in the 1960s by Avedis Donabedian. 2 Shortly thereafter, the National Quality Forum

Full access

Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S. Stefan, Penelope S. Pekow, Peter K. Lindenauer, Supriya G. Mohile, Dilip Babu, and Tara Lagu

prognoses of patients with advanced cancer admitted to the hospital. In this study of hospitalized patients with metastatic cancer who received CCTs, we investigated IPC use and described outcomes (including in-hospital mortality, LOS, discharge

Full access

Gary H. Lyman and David C. Dale

M yeloid growth factors have been used for more than 20 years to ameliorate myelotoxicity after cancer chemotherapy and to prevent infections in patients with chronic neutropenia. Almost all data on long-term outcomes come from studies of

Full access

David J. Worhunsky, Yifei Ma, Yulia Zak, George A. Poultsides, Jeffrey A. Norton, Kim F. Rhoads, and Brendan C. Visser

National Surgical Quality Improvement Project (NSQIP). In general, each program follows the Donabedian 4 , 5 paradigm for measuring health care quality with respect to 1 of 3 domains: structure, process, and outcomes. Although limitations exist with each

Full access

Gary H. Lyman

cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 6 Budman DR Berry DA Cirrincione CT . Dose and dose intensity as determinants of outcome in

Full access

Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults

-adjusted incidence of vSCC is 2.5 per 100,000 women. 3 The most significant prognostic factor for vSCC is lymph node status. 4 , 5 Other factors associated with poor outcomes include age, tumor diameter, tumor depth, tumor class, histologic grade, lymphovascular